Intranasal insulin delivery and therapy1Abbreviations: α-CD, α-cyclodextrin; β-CD, β-cyclodextrin; γ-CD, γ-cyclodextrin; AUC, area under the plasma/serum concentration versus time curve; Cmax, maximum or peak plasma/serum concentration; Cmin, minimum plasma/serum concentration; DDPC, didecanoyl-L-α-phosphatidylcholine; DM-β-CD, dimethyl-β-cyclodextrin; EDTA, ethylenediaminetetraacetic acid; FITC, fluorescein isothiocyanate; HLB, hydrophile–lipophile balance; hGH, human growth hormone; HP-β-CD, hydroxy-propyl-β-cyclodextrin; HPC, hydroxypropylcellulose; HSA, human serum albumin; Hyaff 11, hyaluronic acid ester; IDDM, insulin-dependent diabetes mellitus; Ig, immunoglobulin; Laureth-9, polyoxyethylene-9-lauryl ether; LPC, lysophosphatidylcholine; LPG, lysophosphatidylglycerol; MCC, microcrystalline cellulose; MTR, mucociliary transport rate; NIDDM, non-insulin-dependent diabetes mellitus; PC, phosphatidylcholine; RAMEB, randomly methylated β-cyclodextrin; SDC, sodium deoxycholate; SGC, sodium glycocholate; STDHF, sodium taurodihydrofusidate; 99mTc, 99mtechnetium; TER, transepithelial resistance.1
1999 ◽
Vol 35
(2-3)
◽
pp. 199-234
◽
1999 ◽
Vol 35
(2-3)
◽
pp. 235-247
◽
2009 ◽
Vol 211
(6)
◽
pp. 459-462
◽
1999 ◽
Vol 43
(8)
◽
pp. 2056-2058
◽
1998 ◽
Vol 31
(2)
◽
pp. 178A
1996 ◽
Vol 76
(03)
◽
pp. 328-332
◽
1994 ◽
Vol 130
(6_Suppl)
◽
pp. SS18-SS20
◽